ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026)
ARS Pharmaceuticals (SPRY) reported FCF Margin of 198.17% for Q1 2026, up 31398.0% on a YoY basis from N/an in Q1 2025, and down 28.0% sequentially from 154.82% in Q4 2025.
ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 5 years of FCF Margin data on file, last reported at 198.17% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 31398.0% year-over-year to 198.17%; the trailing twelve-month figure through Mar 2026 stood at 177.11% (down 15544.0% YoY), and the FY2025 full-year result was 203.14%, down 21771.0% from the prior year.
- FCF Margin eased to 198.17% in Q1 2026, from 154.82% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 48.17% in Q4 2024 to a low of 165670.0% in Q2 2023.
- A 5-year average of 18287.87% and a median of 712.19% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin sank 16416224 bps in 2023 and surged 16423080 bps in 2024, its largest moves.
- Tracing SPRY's FCF Margin over 5 years: stood at 3022.22% in 2022, then tumbled by 5382 bps to 165670.0% in 2023, then jumped by 100 bps to 48.17% in 2024, then sank by 421 bps to 154.82% in 2025, then declined by 28 bps to 198.17% in 2026.
- Business Quant data shows SPRY's FCF Margin at 198.17% in Q1 2026, 154.82% in Q4 2025, and 127.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -198.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -198.17% |
| Dec 31, 2025 | -154.82% |
| Sep 30, 2025 | -127.77% |
| Jun 30, 2025 | -288.61% |
| Mar 31, 2025 | -512.14% |
| Dec 31, 2024 | 48.17% |
| Sep 30, 2024 | -712.19% |
| Jun 30, 2024 | -1,439.20% |
| Jun 30, 2023 | -165,670.00% |
| Mar 31, 2023 | -63,110.00% |
| Sep 30, 2022 | -3,022.22% |
| Jun 30, 2022 | -1,507.76% |
| Mar 31, 2022 | -1,047.66% |